Table 1.

Cases of superficial esophageal endocrine cell carcinoma treated by endoscopic resection

Case	Author and reference number	Year	Age	Sex	Resection method	Size, mm	Morphology	Depth	Lymphovascular invasion	Treatment after ER	Recurrence after ER, duration after ER (months)	Prognosis, period (months)
1	Takeshita et al. [15]	2000	73	F	EMR	5	0–IIa	Muscularis mucosa (M3)	None	Carboplatin + etoposide	None	Alive, no recurrence, 28
2	Ozawa and Wachi [16]	2009	78	M	ESD	7	0–IIa	Shallow submucosa (SM1)	None	CPT-11 + CDDP	Abdominal lymph node metastasis, 9	Alive, 9
3	Kobayashi et al. [17]	2011	61	M	ESD	22	0–IIc	Shallow submucosa (SM1)	Yes	5-FU + CDDP, additional surgery, FP + docetaxel, and radiation therapy	Lymph node metastasis around thoracic aorta, 14	Dead, 25
4	Watanabe et al. [4]	2014	55	M	ESD	30	0–IIa + IIc	Deep submucosa	Yes	CPT-11 + CDDP	None	Alive, 55
5	Present case	2017	77	M	ESD	20	0–IIa	Muscularis mucosa (M3)	Yes	Carboplatin + etoposide	Regional lymph node metastasis, 1	Alive, 12

5-FU 5-fluorouracil, CDDP cisplatin, CPT-11 irinotecan, EMR endoscopic mucosal resection, ER endoscopic resection, ESD endoscopic submucosal dissection, F female, FP 5-Fluorouracil plus cisplatin, M male, M3 muscularis mucosae, SM1 submucosa